This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEC0409P_M.jpg
The IPO consists entirely of a fresh issue of 1.09 crore (10.9 million) equity shares by the company. There is no offer-for-sale portion included in this public issue. Investors have the option to bid for a minimum of 105 shares, and in multiples of 105 thereafter.
For retail investors, the minimum investment is set at ₹14,700, equivalent to 105 shares, while the maximum limit is ₹1,91,100 for 1,365 shares. High-net-worth individuals can invest a minimum of ₹2,05,800 and a maximum of ₹9,99,600 at the upper price band.
Valiant Laboratories specializes in active pharmaceutical ingredients (API) and bulk drug manufacturing with a focus on Paracetamol. Dhanvallabh Ventures LLP holds a majority stake of 62.5% in the company. Promoters Shantilal Shivji Vora and Santosh Shantilal Vora each hold a stake of 10.01%. Valiant Organics, listed on BSE and NSE, holds a controlling stake of 73.15% in Dhanvallabh Ventures LLP.
The proceeds raised from the IPO will be used to establish a manufacturing facility for specialty chemicals in Bharuch, Gujarat. This facility will be owned by Valiant’s subsidiary, Valiant Advanced Sciences. The remaining funds from the fresh issue will be allocated towards working capital requirements and general corporate purposes.
The company will open its public issue anchor book for one day on September 26, with the offer closing on October 3. This IPO is expected to be the last in a series of 13 public issues for the current month, which included companies such as Manoj Vaibhav Gems N Jewellers, Sai Silks (Kalamandir), Signature Global, Yatra Online, Zaggle Prepaid Ocean Services, SAMHI Hotels, RR Kabel, EMS, Jupiter Life Line Hospitals, and Ratnaveer Precision Engineering.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
